The excitement over the FDA approval of brexanolone (to be marketed as Zulresso) is a good place to start this week’s roundup. Brexanolone is a derivative of the neurosteroid allopregnanolone, and, while Zulpresso was approved specifically for the treatment of postpartum depression, there is considerable research to indicate that the modulation of neurosteroid systems may… Read More »
This week there are a series of articles related to the recommendations issued by the US Preventive Services Task Force (USPSTF) several weeks ago, stating that all pregnant and postpartum women should be evaluated in order to determine risk for depressive illness and recommends that women at increased risk for perinatal depression should be referred… Read More »
Over the last few years, there has been an increasing number of articles focusing on perinatal anxiety. Recent studies indicate that anxiety during pregnancy and the postpartum period is common and may occur independently of perinatal depression, although anxiety and depressive symptoms frequently appear together during the perinatal period. This week we have several large… Read More »
This week, we have some data from our National Pregnancy Registry of Psychiatric Medications looking at infants exposed to quetiapine (Seroquel). Consistent with other studies we have seen recently, there appears to be no increase in risk of major malformations. There is also an interesting paper from DiFlorio and colleagues which assesses risk for postpartum… Read More »